Tumor Marker Study of Pure Pancreatic Juice in Patient with Pancreatic Diaeases.
- Author:
Sung Koo LEE
;
Myung Hwan KIM
;
Dong Wan SEO
;
Ho Soon CHOI
;
Byeong Moo YOO
;
Mee Hwa LEE
;
Hyung Gun KIM
;
Yong Il MIN
;
Jin Sook RYU
- Publication Type:Original Article
- Keywords:
Pure pancreatic juice;
Tumor markers;
Pancreatic diseases
- MeSH:
Catheterization;
Diagnosis;
Humans;
Pancreatic Diseases;
Pancreatic Ducts;
Pancreatic Juice*;
Pancreatic Neoplasms;
Radioimmunoassay;
Secretin;
Biomarkers, Tumor
- From:Korean Journal of Gastrointestinal Endoscopy
1996;16(2):204-211
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Several reports have described the usefulness of tumor markers detected in pancreatic juice for diagnosis of pancreatic cancer. We performed this study to evaluate the usefulness of tumor markers in pure pancreatic juice collected by duodenoscopic cannulation of pancreatic duct before and after injection of secretin. From April 1993 to July 1995, 8 cases of pancreatic cancer, 5 cases of benign pancreatic lesions, and 5 cases of benign biliary diseases without pancreatic lesion were involved. CEA and CA 19-9 immunoreactivity were measured by radioimmunoassay. Concentrations of CA 19-9 in pure pancreatic juice were significantly higher in patients with pancreatic cancer(median value; 3582, range 88.4-10410 IU/ml) than in control patients(median value 231, range 30.4-682 IU/ml)(p<0.05). Concentrations of CEA in pure pancreatic juice were not significantly different between patients with pancreatic cancer(median value: 6,5, range 1.0-152ng/ml) and control patients(median value: 4.0, range 1-17.2 ng/ml)(p>0.05). There was no significant correlation between levels of CA19-9, CEA in pancreatic juice and those levels in serum. The amounts of juice collected by duodenoscopic cannulation in patients with pancreatic cancer were 1.5+/- 0.9ml during 5 minutes before infusion of secretin, 11.3+/- 3.9ml, 10.8+/- 4.0ml, 10.6+/- 4.0ml in 5 minute interval after infusion of secretin. These results indicated that measurement of CA19-9 in pure pancreatic juice may be used as a marker for pancreatic cancer. Adequate amount of pancreatic juice was collected by duodenoscopic cannulation for evaluation of tumor marker, enzyme studies and cytology.
